{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T10:57:35Z","timestamp":1780484255487,"version":"3.54.1"},"reference-count":36,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2012,11,22]],"date-time":"2012-11-22T00:00:00Z","timestamp":1353542400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Seminars in Dialysis"],"published-print":{"date-parts":[[2013,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>L\u2010Carnitine (LC) administration has been recommended for specific indications in dialysis patients, including epoetin\u2010resistant anemia, intradialytic hypotension, cardiomyopathy, fatigue, muscle weakness, and exercise performance; it may ameliorate insulin resistance, inflammation, and protein wasting. Use of LC for anemia and intradialytic hypotension has been approved for reimbursement by the Centers for Medicare and Medicaid Services. Yet, the data to support these recommendations are inadequate and have not been bolstered over several decades. LC administration continues to appeal to nephrologists because its use in dialysis patients has an attractive rationale, it addresses problems that persist despite dialysis, it is safe, and the existing literature does not refute its use. Nevertheless, definitive trials to justify LC administration have not been conducted and are increasingly unlikely to be funded. In an era of shrinking resources and bundling of dialysis services, the use of LC in dialysis patients will, appropriately, diminish.<\/jats:p>","DOI":"10.1111\/sdi.12041","type":"journal-article","created":{"date-parts":[[2012,11,23]],"date-time":"2012-11-23T03:29:40Z","timestamp":1353641380000},"page":"11-15","source":"Crossref","is-referenced-by-count":19,"title":["L\u2010Carnitine Supplementation in Dialysis: Treatment in Quest of Disease"],"prefix":"10.1111","volume":"26","author":[{"given":"Alan G.","family":"Wasserstein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,11,22]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1990.289"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1990.290"},{"key":"e_1_2_7_4_2","unstructured":"Food and Drug Administration Center for Drug Evaluation and Research: FDA approval letter for carnitor injection in dialysis. Available athttp:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/1999\/20182S6LTR.PDF accessed November 7 2012"},{"key":"e_1_2_7_5_2","unstructured":"U.S. Department of Health and Human Services Center for Medicare and Medicaid Services: Decision Memo for Levocarnitine for End Stage Renal Disease. Available athttp:\/\/www.unk.edu\/academics\/library.aspx?id=14245 accessed November 7 2012"},{"key":"e_1_2_7_6_2","first-page":"177","article-title":"Role of L\u2010carnitine in treating renal dialysis patients","volume":"23","author":"AAKP Carnitine Renal Dialysis Consensus Group","year":"1994","journal-title":"Dial Transplant"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-6386(03)00110-0"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-6386(03)00113-6"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-1755.2004.00916.x"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1159\/000186280"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.96.5.2356"},{"issue":"1","key":"e_1_2_7_12_2","first-page":"S2","article-title":"Analysis of free carnitine in plasma of ESRD patients undergoing chronic dialysis: what is the best assay?","volume":"32","author":"Fornasini GF","year":"2003","journal-title":"Dial Transplant"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1159\/000089450"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1081\/JDI-100100853"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfh758"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfm707"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1542-4758.2012.00679.x"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/0272-6386(95)90439-5"},{"key":"e_1_2_7_19_2","first-page":"498","article-title":"Effects of L\u2010carnitine on anemia in aged hemodialysis patients treated with recombinant human erythropoietin: a pilot study","volume":"27","author":"Caruso U","year":"1998","journal-title":"Dial Transplant"},{"key":"e_1_2_7_20_2","doi-asserted-by":"crossref","first-page":"S93","DOI":"10.1038\/sj.ki.4490857","article-title":"Anemia and carnitine supplementation in hemodialyzed patients","volume":"69","author":"Kletzmayr J","year":"1999","journal-title":"Kidney Int"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1159\/000078399"},{"key":"e_1_2_7_22_2","first-page":"470","article-title":"Evaluation of the effect of intravenous L\u2010carnitine on quality of life in chronic hemodialysis patients","volume":"54","author":"Semeniuk J","year":"2000","journal-title":"Clin Nephrol"},{"key":"e_1_2_7_23_2","first-page":"21454","article-title":"The role of oral L\u2010carnitine therapy in chronic hemodialysis patients","volume":"21","author":"Sabry AA","year":"2010","journal-title":"Saudi J Kidney Dis Transpl"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-006-0408-8"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.V133708"},{"key":"e_1_2_7_26_2","unstructured":"BernsJS:Non\u2010iron pharmacologic adjuvants to erythropoiesis stimulating agent therapy in dialysis patients. Available athttp:\/\/www.uptodate.com\/contents\/non\u2010iron\u2010pharmacologic\u2010adjuvants\u2010to\u2010erythropoiesis\u2010stimulating\u2010agent\u2010therapy\u2010in\u2010dialysis\u2010patients?source=search_result&search=non+iron+pharmacologic+adjuvants+to+erythropoiesis+stimulating+agent+therapy+in+dialysispatients&selectedTitle=2%7E150 accessed November 7 2012"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2008.08.008"},{"key":"e_1_2_7_28_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2008.05.031"},{"key":"e_1_2_7_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/0735-1097(95)80010-E"},{"key":"e_1_2_7_30_2","doi-asserted-by":"publisher","DOI":"10.3109\/00365518509160991"},{"key":"e_1_2_7_31_2","doi-asserted-by":"publisher","DOI":"10.1177\/014860710603000110"},{"key":"e_1_2_7_32_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfm664"},{"key":"e_1_2_7_33_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.jrn.2004.10.002"},{"key":"e_1_2_7_34_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfl356"},{"key":"e_1_2_7_35_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.jrn.2011.01.001"},{"key":"e_1_2_7_36_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1525-139x.2002.0020a.x"},{"key":"e_1_2_7_37_2","first-page":"28","article-title":"L\u2010carnitine use in dialysis patients: is national coverage of supplementation justified? What were the CMS regulators thinking\u2014or were they?","volume":"17","author":"Steinman TI","year":"2003","journal-title":"Nephrol News Issues"}],"container-title":["Seminars in Dialysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fsdi.12041","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/sdi.12041","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T17:40:07Z","timestamp":1697305207000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/sdi.12041"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11,22]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,1]]}},"alternative-id":["10.1111\/sdi.12041"],"URL":"https:\/\/doi.org\/10.1111\/sdi.12041","archive":["Portico"],"relation":{},"ISSN":["0894-0959","1525-139X"],"issn-type":[{"value":"0894-0959","type":"print"},{"value":"1525-139X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,11,22]]}}}